Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial

著者: Cory A. Perugino, Zachary S. Wallace, Debra Zack, Shauna M Quinn, Allen Poma, Ana D. Fernandes, Paul Foster, Steve DeMattos, Bart Burington, Hang Liu, Hugues Allard‐Chamard, Nathan Smith, Xin Kai, Kelly Xing, Shiv Pillai, John H. Stone - The Lancet 2023 被引用: 66